Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 53
- Registration Number
- NCT06451211
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 30
- Registration Number
- NCT06446726
A Phase 1 Study of BGB-B2033, Alone or in Combination with Tislelizumab, in Participants with Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 140
- Registration Number
- NCT06427941
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 62
- Registration Number
- NCT06422520
- Locations
- 🇺🇸
Florida Cancer Specialist Research Institute Lake Nona, Orlando, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
- Conditions
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Chen Xiaoping
- Target Recruit Count
- 160
- Registration Number
- NCT06420440
Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- National Cancer Center, China
- Target Recruit Count
- 29
- Registration Number
- NCT06414915
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 392
- Registration Number
- NCT06416410
- Locations
- 🇨🇳
Anhui Province cancer hospital, Hefei, Anhui, China
🇨🇳Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
- Conditions
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06396585
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 46
- Registration Number
- NCT06390982
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 40
- Registration Number
- NCT06387056
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.